참고문헌
- Brooks CL, Gu W (2006). p53 ubiquitination: Mdm2 and beyond. Mol Cell, 21, 307-15. https://doi.org/10.1016/j.molcel.2006.01.020
- Chansaenroj J, Lurchachaiwong W, Termrungruanglert W, et al (2010). Prevalence and genotypes of human papillomavirus among Thai women. Asian Pac J Cancer Prev, 11, 117-22.
- Chattopadhyay K (2011). A comprehensive review on host genetic susceptibility to human papillomavirus infection and progression to cervical cancer. Indian J Hum Genet, 17, 132-44. https://doi.org/10.4103/0971-6866.92087
- Chansaenroj J, Theamboonlers A, Junyangdikul P, et al (2012). Whole genome analysis of human papillomavirus type 16 multiple infection in cervical cancer patients. Asian Pac J Cancer Prev, 13, 599-606. https://doi.org/10.7314/APJCP.2012.13.2.599
- Chao C, Zhang ZF, Berthiller J, Boffetta P, Hashibe M (2006). NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 15, 979-87. https://doi.org/10.1158/1055-9965.EPI-05-0899
- Eltahir HA, Elhassan AM, Ibrahim ME (2012). Contribution of retinoblastoma LOH and the p53 Arg/Pro polymorphism to cervical cancer. Mol Med Report, 6, 473-6.
- Geddert H, Kiel S, Zotz RB, et al (2005). Polymorphism of p16 INK4A and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol, 131, 803-8. https://doi.org/10.1007/s00432-005-0021-4
- Hemminki K, Dong C, Vaittinen P (1999). Familial risks in cervical cancer: Is there a hereditary component? Int J Cancer, 82, 775-81. https://doi.org/10.1002/(SICI)1097-0215(19990909)82:6<775::AID-IJC1>3.0.CO;2-V
- Hu X, Zhang Z, Ma D, et al (2010). TP53, MDM2, NQO1, and susceptibility to cervical cancer. Cancer Epidemiol Biomarkers Prev, 19, 755-61. https://doi.org/10.1158/1055-9965.EPI-09-0886
- Jee SH, Won SY, Yun JE, et al (2004). Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis. Int J Gynaecol Obstet, 85, 301-8. https://doi.org/10.1016/j.ijgo.2003.08.017
- Kelsey KT, Ross D, Traver RD, et al (1997). Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anticancer chemotherapy. Br J Cancer, 76, 852-54. https://doi.org/10.1038/bjc.1997.474
- Kohaar I, Thakur N, Salhan S, et al (2007). TNFalpha-308G/A polymorphism as a risk factor for HPV associated cervical cancer in Indian population. Cell Oncol, 29, 249-56.
- Koushik A, Platt RW, Franco EL (2004). p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev, 13, 11-22. https://doi.org/10.1158/1055-9965.EPI-083-3
- Koshiol J, Lindsay L, Pimenta JM, et al (2008). Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol, 168, 123-37. https://doi.org/10.1093/aje/kwn036
- Koshiol J, Hildesheim A, Gonzalez P, et al (2009). Common genetic variation in TP53 and risk of human papillomavirus persistence and progression to CIN3/cancer revisited. Cancer Epidemiol Biomarkers Prev, 18, 1631-7. https://doi.org/10.1158/1055-9965.EPI-08-0830
- Lafuente MJ, Casterad X, Trias M, et al (2000). NAD(P) H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis, 21, 1813-9. https://doi.org/10.1093/carcin/21.10.1813
- Makni H, Franco EL, Kaiano J, et al (2000). P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int J Cancer, 87, 528-33. https://doi.org/10.1002/1097-0215(20000815)87:4<528::AID-IJC11>3.0.CO;2-O
- Magnusson PK, Sparen P, Gyllensten UB (1999). Genetic link to cervical tumours. Nature, 400, 29-30. https://doi.org/10.1038/21801
- Meek DW (2009). Tumor suppression by p53: a role for the DNA damage response? Nat Rev Cancer, 9, 714-23.
- Narisawa-Saito M, Kiyono T (2007). Basic mechanisms of highrisk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci, 98, 1505-11. https://doi.org/10.1111/j.1349-7006.2007.00546.x
- Niwa Y, Hirose K, Nakanishi T, et al (2005). Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects. Gynecol Oncol, 96, 423-9. https://doi.org/10.1016/j.ygyno.2004.10.015
- Ojeda JM, Ampuero S, Rojas P, et al (2003). p53 codon 72 polymorphism and risk of cervical cancer. Biol Res, 36, 279-83.
- Oliveira S, Sousa H, Santos AM, et al (2008). The p53 R72P polymorphism does not influence cervical cancer development in a Portuguese population: a study in exfoliated cervical cells. J Med Virol, 80, 24-9.
- Pina-Sanchez P, Hernandez-Hernandez DM, Taja-Chayeb L, et al (2011). Polymorphism in exon 4 of TP53 gene associated to HPV 16 and 18 in Mexican women with cervical cancer. Med Oncol, 28, 1507-13. https://doi.org/10.1007/s12032-010-9599-8
- Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH (1995). Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics, 5, 199-206. https://doi.org/10.1097/00008571-199508000-00003
- Rogler A, Rogenhofer M, Borchardt A, et al (2011). P53 codon 72 (Arg72Pro) polymorphism and prostate cancer risk: association between disease onset and proline genotype. Pathobiology, 78, 193-200. https://doi.org/10.1159/000326767
- Sauroja I, Smeds J, Vlaykova T, et al (2000). Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer, 28, 404-4. https://doi.org/10.1002/1098-2264(200008)28:4<404::AID-GCC6>3.0.CO;2-P
- Schulz WA, Krummeck A, Rosinger I, et al (1997). Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics, 7, 235-9. https://doi.org/10.1097/00008571-199706000-00008
- Siegel D, McGuinness SM, Winski SL, Ross D (1999). Genotypephenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics, 9, 113-21. https://doi.org/10.1097/00008571-199902000-00015
- Sousa H, Santos AM, Pinto D, Medeiros R (2011). Is there a biological plausibility for p53 codon 72 polymorphism influence on cervical cancer development? Acta Med Port, 24, 127-34.
- Sousa H, Santos AM, Pinto D, Medeiros R (2007). Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations. Int J Mol Med, 20, 731-41.
- Storey A, Thomas M, Kalita A, et al (1998). Role of a p53 polymorphism in the development of human papillomavirusassociated cancer. Nature, 393, 229-34. https://doi.org/10.1038/30400
- Thakur N, Hussain S, Nasare V, et al (2012). Association analysis of p16 (CDKN2A) and RB1 polymorphisms with susceptibility to cervical cancer in Indian population. Mol Biol Rep, 39, 407-14. https://doi.org/10.1007/s11033-011-0752-z
- Thomas M, Kalita A, Labrecque S, et al (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol, 19, 1092-100.
- Thurow HS, Haack R, Hartwig FP, et al (2011). TP53 gene polymorphism: importance to cancer, ethnicity and birth weight in a Brazilian cohort. J Biosci, 36, 823-31. https://doi.org/10.1007/s12038-011-9147-5
- Tsvetkov P, Reuven N, Shaul Y (2010). Ubiquitin-independent p53 proteasomal degradation. Cell Death Differ, 17, 103-8. https://doi.org/10.1038/cdd.2009.67
- Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
- Yan L, Na W, Shan K, et al (2008). p16 (CDKN2) gene polymorphism: association with histologic subtypes of epithelial ovarian cancer in China. Int J Gynecol Cancer, 18, 30-5. https://doi.org/10.1111/j.1525-1438.2007.00953.x
- Zheng Y, Shen H, Sturgis EM, et al (2002). Haplotypes of two variants in p16 (CDKN2/MTS-1/INK4a) exon 3 and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Epidemiol Biomarkers Prev, 11, 640-5.
피인용 문헌
- SCYL1BP1 has Tumor-suppressive Functions in Human Lung Squamous Carcinoma Cells by Regulating Degradation of MDM2 vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7467
- Analysis of TP53 Polymorphisms in North Indian Sporadic Esophageal Cancer Patients vol.15, pp.19, 2014, https://doi.org/10.7314/APJCP.2014.15.19.8413
- polymorphisms with the severity of cervical neoplasia in a Brazilian population vol.19, pp.2, 2014, https://doi.org/10.3109/1354750X.2014.881419
- Association between p16(CDKN2A) C540G polymorphism and tumor behavior in prolactinoma: A single-center study vol.2, pp.4, 2014, https://doi.org/10.3892/br.2014.281
- Evidence for an Epistatic Effect between TP53 R72P and MDM2 T309G SNPs in HIV Infection: A Cross-Sectional Study in Women from South Brazil vol.9, pp.2, 2014, https://doi.org/10.1371/journal.pone.0089489
- Analysis of somatic mutations in BRAF, CDKN2A/p16 and PI3KCA in patients with medullary thyroid carcinoma vol.13, pp.2, 2015, https://doi.org/10.3892/mmr.2015.4731
- Lack of Associations between TNF-α Polymorphisms and Cervical Cancer in Thai women vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.953
- CD38 enhances the proliferation and inhibits the apoptosis of cervical cancer cells by affecting the mitochondria functions vol.56, pp.10, 2017, https://doi.org/10.1002/mc.22677
- Association of p16 (CDKN2A) polymorphisms with the development of HPV16-related precancerous lesions and cervical cancer in the Greek population pp.01466615, 2017, https://doi.org/10.1002/jmv.24996